retifanlimab,pembrolizumab,Bria-IMT
Incyte,Merck,BriaCell Therapeutics
['breast']
briacell (nasdaq: $bctx) presents positive data demonstrating survival and clinical benefits in advanced metastatic breast cancer at the 2023 aacr. find out more about the potential clinical value of the bria-mt regimen: #stocks #stocktowatch #biotech 
Never buy or sell based off of any tweets from SmallCapVoice. Do your own DD before buying or selling in the stock market. Disclaimer https://t.co/4gsISV4JVq